WST Stock Recent News
WST LATEST HEADLINES
Medical equipment maker West Pharmaceutical Services on Thursday raised its 2023 adjusted profit forecast for a third time, benefiting from a stronger dollar.
West Pharmaceutical's (WST) third-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
West Pharmaceutical Services, Inc. has experienced a 60% gain in its stock price so far in 2023 but has hit some recent technical headwinds. Insiders have also sold a significant number of shares in August and September, and the stock's free cash flow yield is dwarfed to what is available in short-term treasuries. The stock also seems stretched based on its current P/E and price-to-sales valuation metrics.
Expert presentations and posters offer thought leadership in drug delivery innovation, patient adherence and pharmaceutical manufacturing EXTON, Pa. , Oct. 16, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced participation in the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Gothenburg, Sweden to showcase its leadership and expertise on industry challenges and trends in packaging and containment.
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Although these companies are from different sectors, we compare them because they have a similar market capitalization of around $30 billion.
EXTON, Pa. , Sept. 7, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at Bank of America Global Healthcare Conference in London, UK on Thursday, September 14, 2023 at 10:50 AM BST.
West Pharmaceutical's (WST) strength in its proprietary products segment raises optimism about the stock.
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
West Pharmaceutical Services has seen a 60% rally in its stock price since December 2022, outperforming the S&P 500. Momentum in financials shows a decline in top line sales but strong growth in contract-manufactured revenues and free cash flow. The company has demonstrated the ability to compound value for shareholders and has attractive technical indicators for future growth.